Resumen de acción CXXI
C21 Investments Inc. es una empresa integrada de cannabis que cultiva, procesa, distribuye y vende cannabis y productos de consumo derivados del cáñamo en Estados Unidos.
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 4/6 |
| Dividendos | 0/6 |
Competidores de C21 Investments Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | CA$0.30 |
| Máximo en las últimas 52 semanas | CA$0.64 |
| Mínimo de 52 semanas | CA$0.27 |
| Beta | 2.3 |
| 1Cambio en 1 mes | -1.64% |
| Variación en 3 meses | -21.05% |
| Cambio de 1 año | -4.76% |
| 3Variación en 3 años | -62.50% |
| Variación en 5 años | -55.22% |
| Variación desde la OPV | -98.80% |
Noticias y actualizaciones recientes
Subdued Growth No Barrier To C21 Investments Inc.'s (CSE:CXXI) Price
Sep 12
C21 Investments Inc.'s (CSE:CXXI) 30% Share Price Surge Not Quite Adding Up
May 12Recent updates
Subdued Growth No Barrier To C21 Investments Inc.'s (CSE:CXXI) Price
Sep 12C21 Investments Inc.'s (CSE:CXXI) 30% Share Price Surge Not Quite Adding Up
May 12A Look At The Intrinsic Value Of C21 Investments Inc. (CSE:CXXI)
May 01Some Confidence Is Lacking In C21 Investments Inc. (CSE:CXXI) As Shares Slide 27%
Mar 09Is C21 Investments (CSE:CXXI) A Risky Investment?
Sep 04These 4 Measures Indicate That C21 Investments (CSE:CXXI) Is Using Debt Reasonably Well
Mar 21These 4 Measures Indicate That C21 Investments (CSE:CXXI) Is Using Debt Reasonably Well
Nov 29C21 Investments Inc. (CSE:CXXI) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
Oct 12A Look At The Fair Value Of C21 Investments Inc. (CSE:CXXI)
Apr 22Does C21 Investments (CSE:CXXI) Have A Healthy Balance Sheet?
Mar 22C21 Investments' (CSE:CXXI) Solid Earnings May Rest On Weak Foundations
Oct 05We Think C21 Investments (CSE:CXXI) Can Stay On Top Of Its Debt
Sep 03C21 Investments (CSE:CXXI) Seems To Use Debt Quite Sensibly
Mar 07Rentabilidad de los accionistas
| CXXI | CA Pharmaceuticals | Mercado CA | |
|---|---|---|---|
| 7D | 0% | -4.7% | -1.5% |
| 1Y | -4.8% | 17.0% | 21.1% |
Rentabilidad vs. Industria: CXXI underperformed the Canadian Pharmaceuticals industry which returned 17% over the past year.
Rentabilidad vs. Mercado: CXXI underperformed the Canadian Market which returned 21.1% over the past year.
Volatilidad de los precios
| CXXI volatility | |
|---|---|
| CXXI Average Weekly Movement | 14.8% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.5% |
| 10% least volatile stocks in CA Market | 2.9% |
Precio estable de las acciones: CXXI's share price has been volatile over the past 3 months compared to the Canadian market.
Volatilidad a lo largo del tiempo: CXXI's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1987 | 114 | Sonny Newman | www.cxxi.ca |
C21 Investments Inc, una empresa integrada de cannabis, cultiva, procesa, distribuye y vende cannabis y productos de consumo derivados del cáñamo en los Estados Unidos. La empresa ofrece CO2, resina viva, destilado, resina curada CBD y bolígrafos vaporizadores CBD CO2; extractos de resina viva, curada y curada CBD; flores a granel, al por mayor y envasadas; comestibles; pre-rolls; tinturas; y tópicos. También ofrece servicios de nóminas y prestaciones.
Resumen de fundamentos de C21 Investments Inc.
| Estadísticas fundamentales de CXXI | |
|---|---|
| Capitalización bursátil | CA$36.01m |
| Beneficios(TTM) | -CA$430.74k |
| Ingresos (TTM) | CA$37.39m |
1.0x
Ratio precio-ventas (PS)-83.6x
Ratio precio-beneficio (PE)¿Está CXXI sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CXXI | |
|---|---|
| Ingresos | US$26.79m |
| Coste de los ingresos | US$17.58m |
| Beneficio bruto | US$9.21m |
| Otros gastos | US$9.52m |
| Beneficios | -US$308.63k |
Últimos beneficios comunicados
Mar 31, 2024
Próxima fecha de beneficios
Nov 15, 2024
| Beneficios por acción (BPA) | -0.0026 |
| Margen bruto | 34.38% |
| Margen de beneficio neto | -1.15% |
| Ratio deuda/patrimonio | 3.7% |
¿Cómo se ha desempeñado CXXI a largo plazo?
Ver rendimiento histórico y comparativa